# OnCo record ruxolitinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ruxolitinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ruxolitinib" ;
  schema:name "Ruxolitinib"@en ;
  schema:description "Ruxolitinib was the first JAK inhibitor: it shrinks the spleen and relieves symptoms in myelofibrosis and controls blood counts in polycythaemia vera, without eliminating the disease clone."@en ;
  schema:url <https://onco.cc/drugs/ruxolitinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ruxolitinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7383611> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1110557>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ruxolitinib> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule JAK1/JAK2 inhibitor" ;
  schema:alternateName "Jakafi / Jakavi" ;
  onco:approval "US 2011: Intermediate/high-risk myelofibrosis", "US 2014: Polycythaemia vera after hydroxyurea", "US 2019: Steroid-refractory acute GVHD", "US 2021: Chronic GVHD after failure of 1-2 lines", "EU 2012: Myelofibrosis" ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/polycythaemia-vera/>, <https://onco.cc/cancers/primary-myelofibrosis/>, <https://onco.cc/cancers/all-ph-like/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:targets <https://onco.cc/targets/jak2/>, <https://onco.cc/targets/jak1/> ;
  onco:companies <https://onco.cc/companies/incyte/>, <https://onco.cc/companies/novartis/> ;
  onco:trials <https://onco.cc/trials/nct02955940/>, <https://onco.cc/trials/nct04562389/>, <https://onco.cc/trials/nct04509700/>, <https://onco.cc/trials/nct04817007/>, <https://onco.cc/trials/nct03669965/> .